1. Proteolytic bacteria expansion during colitis amplifies inflammation through cleavage of the external domain of PAR2
- Author
-
Liam Emile Rondeau, Bruna Barbosa Da Luz, Alba Santiago, Miriam Bermudez-Brito, Amber Hann, Giada De Palma, Jennifer Jury, Xuanyu Wang, Elena Francisca Verdu, Heather Jean Galipeau, Corinne Rolland, Celine Deraison, Wolfram Ruf, Premysl Bercik, Nathalie Vergnolle, and Alberto Caminero
- Subjects
Inflammatory bowel disease ,proteolytic activity ,inflammation ,colitis ,DSS-induced colitis ,protease-activated receptor 2 (PAR2) ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Imbalances in proteolytic activity have been linked to the development of inflammatory bowel diseases (IBD) and experimental colitis. Proteases in the intestine play important roles in maintaining homeostasis, but exposure of mucosal tissues to excess proteolytic activity can promote pathology through protease-activated receptors (PARs). Previous research implicates microbial proteases in IBD, but the underlying pathways and specific interactions between microbes and PARs remain unclear. In this study, we investigated the role of microbial proteolytic activation of the external domain of PAR2 in intestinal injury using mice expressing PAR2 with a mutated N-terminal external domain that is resistant to canonical activation by proteolytic cleavage. Our findings demonstrate the key role of proteolytic cleavage of the PAR2 external domain in promoting intestinal permeability and inflammation during colitis. In wild-type mice expressing protease-sensitive PAR2, excessive inflammation leads to the expansion of bacterial taxa that cleave the external domain of PAR2, exacerbating colitis severity. In contrast, mice expressing mutated protease-resistant PAR2 exhibit attenuated colitis severity and do not experience the same proteolytic bacterial expansion. Colonization of wild-type mice with proteolytic PAR2-activating Enterococcus and Staphylococcus worsens colitis severity. Our study identifies a previously unknown interaction between proteolytic bacterial communities, which are shaped by inflammation, and the external domain of PAR2 in colitis. The findings should encourage new therapeutic developments for IBD by targeting excessive PAR2 cleavage by bacterial proteases.
- Published
- 2024
- Full Text
- View/download PDF